News

NMC Health Stock Start 2020 as they Ended 2019: Down

One of the most heavily shorted stocks in the FTSE 100 and United Arab Emirates’ largest private healthcare provider share price dropped significantly in December and January. More than £2bn was wiped from the value of NMC Health PLC (LON: NMC) after there were “serious doubts” about the group’s finances in a report by US…
Read More

Why more African countries should consider Fintech: the case of M-Pesa in Kenya

Sub-Saharan Africa suffer from significant levels of financial exclusion, in particular concerning bank-based activity. Traditional banking have failed to comprehensively understand their customers’ needs and to assess financial risks, resulting in less accurate financial service provision. The positive outcome of the introduction of M-Pesa on the Kenyan economy and consumers, however, shows that other sub-Saharan…
Read More

Russia’s newly-elected Prime Minister and record-low bond yields

On 15 January, Putin’s state-of-the-union speech took Kremlin-watchers by surprise. He announced the resignation of former Prime Minister Dmitry Medvedev along with the entire cabinet, as well as a number of constitutional reforms. The latter includes granting parliament greater powers over the cabinet, judges and security services, and increased powers to the State Council. This…
Read More

Blame After Last Year’s Blackout

Following an investigation by Britain’s energy regulator Ofgem in response to a widespread power outage last August, three companies will pay a combined fine of £10.5m into a consumer redress fund. Ofgem found the widespread chaos resulting from the power cut left more than one million customers without power and caused significant travel disorder. The…
Read More

What next for the UK? Conservative Party Policy and connected impacts in a post-Brexit world.

The morning of Thursday 12th December saw Boris Johnson’s Conservative Party steam to victory over Jeremy Corbyn’s Labour, gaining a substantial majority of eighty lawmakers. Speaking in his maiden address of this parliament he promised to work ‘round the clock’ to repay his voters, calling for ‘[Brexit] healing to begin’. He hinted at many other…
Read More

Why the Recent Price Rise in Prescription Drugs is Not as High as Expected

In the start of the year most pharmaceutical firms have introduced price increases to many of their prescription drugs. Many drug makers, such as Pfizer, AbbVie and Allergan PLC, have all posted price increases on 1376 drug products in total, and counting, for the new year, with an average price increase of 5% on last…
Read More

Trump’s tariffs target Brazil and Argentina; amid rising concerns over the future of the US farming industry

On Monday, American President Donald Trump announced the decision to-reinstate tariffs of 25% on steel and 10% on aluminium coming from Argentina and Brazil, a proposal which failed to materialise last year for the two countries due to the ardent frustration of many domestic consumers at the idea of having to pay higher prices. Nonetheless,…
Read More

The Untapped Mineral Fortune Under North Korea

Despite the economy of North Korea estimated to be roughly forty times smaller than that of the South, North Korea has the advantage in one field – mineral wealth. With the second largest magnesite deposit in the world, North Korea also has abundance of metals such as zinc, tungsten, iron, as well as sizeable deposits…
Read More

The biggest IPO in history: Saudi Aramco

‘The most profitable company in the world’ has now become the most valuable firm in the world. After raising $25.6bn in the world’s biggest IPO for a 1.5% stake, Saudi Aramco – the biggest oil company in the world – is now valued at a whopping $1.7tn. Although this falls below the initial expectations of…
Read More

Is the Acquisition of The Medicines Company Good or Bad Cholesterol for Novartis?

Novartis – a Swiss multinational pharmaceutical company based in Basel – has agreed a $9.7bn cash deal to acquire The Medicines Company. This US-based pharmaceutical company has been focusing on a new drug called Inclisiran which controls cholesterol levels. Novartis will pay $85 per share in cash which represents a premium of around 41% over…
Read More